Monday, October 5, 2026

Micron's 2026 HBM Output Is Fully Sold Out

Micron says its entire High Bandwidth Memory production for 2026 has already been sold, signaling AI accelerator demand is outrunning memory supply. The sellout comes as Sanjay Mehrotra leads Micron through the AI-driven memory upcycle, positioning HBM as a chokepoint for AI chip scaling.

LM Salvado

July 3, 2026

Micron's 2026 HBM Output Is Fully Sold Out
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Micron's High Bandwidth Memory output for 2026 is completely sold out, the company says.1 HBM chips stack memory directly next to AI accelerators, feeding data to processors like Nvidia's GPUs faster than standard DRAM.

A full sellout more than a year ahead of production means buyers are locking in supply before it exists. That points to AI accelerator demand outpacing memory manufacturers' ability to build capacity.1

Micron CEO Sanjay Mehrotra is steering the company through this demand surge.2 HBM has become a structural bottleneck in AI hardware: chipmakers can design faster processors, but those chips are useless without enough high-speed memory to feed them.

The sellout suggests Micron's HBM segment could grow faster than its overall DRAM business in coming quarters. If HBM revenue and margins expand faster than the rest of Micron's memory portfolio, it would confirm AI accelerator buyers are paying a premium to secure scarce supply.

Analysts tracking the company will watch Micron's next two to three quarterly earnings reports for HBM segment revenue growth and gross margin expansion relative to prior guidance.1 A widening gap between HBM growth and total DRAM growth would confirm memory, not chip design, is now the binding constraint on AI accelerator output.

The dynamic matters beyond Micron. If HBM supply is committed through 2026, competitors racing to ship AI chips - and cloud providers racing to deploy them - face a shared ceiling on how fast they can scale, regardless of processor availability.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com